FT – Ten Esports Predictions Worth Looking Forward To!

 


Ten Esports Predictions Worth Looking Forward To!

 

Globally, esports revenues are predicted to grow to $1,084 million in 2021. In terms percentage terms, that’s expected growth of 14.5% from $947.1 million in 2020.

The global average revenue per esports fan will be $4.63 this year, up +2.8% from $4.40 in 2020. Note that this is down from 2019’s $4.86 per esports enthusiast.  Newzoo.com, by which most of these predictions were made, expects it to reach $5.25 in 2021 after live events are restored.

Media rights and sponsorship is expected to bring in $833.6 million in revenues during 2021. This would represent 75% of total revenue from this industry. 

The global games’ live-streaming audience is expected to hit 728.8 million this year (2021). That is 10% growth from 2020.

The largest growth in live broadcast last year was in the Spanish and Portuguese language market. This places them after English as the most-watched languages on live-streaming platforms. Spanish grew by +369% to reach 1.4 billion hours watched, while Portuguese grew by +189% to 1.1 billion hours.

Globally, the total esports audience should grow to 474.0 million people in 2021. That’s a predicted YOY growth of +8.7%.

China is expected to have the most esports fans in 2021, with 92.8 million. They’ll be followed by the U.S. and Brazil. China should also be the largest market for live-streaming games live, with an audience of 193.0 million in 2021.

China is expected to be the largest esports entertainment market by revenues, with total revenues increasing by 14% to of $360.1 million in 2021. North America follows with predicted total revenues of $243.0 million, and Western Europe, with revenues of $205.8 million.

The League of Legends World Championship was 2020’s biggest tournament based on live viewership hours on Twitch and YouTube, with a total of 91.9 million hours. League of Legends Champions Korea was the most-watched league by live viewership hours on Twitch and YouTube, generating 53.8 million hours.

The global average revenue per esports enthusiast will be $4.63 this year, up +2.8% from $4.40 in 2020. It is important to note this is down from 2019’s $4.86 per esports enthusiast, but we expect it to jump up to $5.25 in 2021 after live events are restored.

Attend Live:

Virtual Road Show Series – Wednesday March 31 @ 1pm EDT

Join Esports Entertainment Group (GMBL) CEO Grant Johnson for this exclusive corporate presentation, followed by a Q & A session moderated by Michael Kupinski, Noble’s senior research analyst, featuring questions taken from the audience. Registration is free and open to all investors, at any level.

Register Now  |  View All Upcoming Road Shows

 

Source: 2021 Newzoo 10 Global Esports & Live Streaming Market Report 2021 PRESS COPY Key Takeaways

 

More to Discover on Channelchek:

College Scholarships for Esports Gamers

How to Invest in Esports

 

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Ten Esports Predictions Worth Looking Forward To!

 


Ten Esports Predictions Worth Looking Forward To!

 

Globally, esports revenues are predicted to grow to $1,084 million in 2021. In terms percentage terms, that’s expected growth of 14.5% from $947.1 million in 2020.

The global average revenue per esports fan will be $4.63 this year, up +2.8% from $4.40 in 2020. Note that this is down from 2019’s $4.86 per esports enthusiast.  Newzoo.com, by which most of these predictions were made, expects it to reach $5.25 in 2021 after live events are restored.

Media rights and sponsorship is expected to bring in $833.6 million in revenues during 2021. This would represent 75% of total revenue from this industry. 

The global games’ live-streaming audience is expected to hit 728.8 million this year (2021). That is 10% growth from 2020.

The largest growth in live broadcast last year was in the Spanish and Portuguese language market. This places them after English as the most-watched languages on live-streaming platforms. Spanish grew by +369% to reach 1.4 billion hours watched, while Portuguese grew by +189% to 1.1 billion hours.

Globally, the total esports audience should grow to 474.0 million people in 2021. That’s a predicted YOY growth of +8.7%.

China is expected to have the most esports fans in 2021, with 92.8 million. They’ll be followed by the U.S. and Brazil. China should also be the largest market for live-streaming games live, with an audience of 193.0 million in 2021.

China is expected to be the largest esports entertainment market by revenues, with total revenues increasing by 14% to of $360.1 million in 2021. North America follows with predicted total revenues of $243.0 million, and Western Europe, with revenues of $205.8 million.

The League of Legends World Championship was 2020’s biggest tournament based on live viewership hours on Twitch and YouTube, with a total of 91.9 million hours. League of Legends Champions Korea was the most-watched league by live viewership hours on Twitch and YouTube, generating 53.8 million hours.

The global average revenue per esports enthusiast will be $4.63 this year, up +2.8% from $4.40 in 2020. It is important to note this is down from 2019’s $4.86 per esports enthusiast, but we expect it to jump up to $5.25 in 2021 after live events are restored.

Attend Live:

Virtual Road Show Series – Wednesday March 31 @ 1pm EDT

Join Esports Entertainment Group (GMBL) CEO Grant Johnson for this exclusive corporate presentation, followed by a Q & A session moderated by Michael Kupinski, Noble’s senior research analyst, featuring questions taken from the audience. Registration is free and open to all investors, at any level.

Register Now  |  View All Upcoming Road Shows

 

Source: 2021 Newzoo 10 Global Esports & Live Streaming Market Report 2021 PRESS COPY Key Takeaways

 

More to Discover on Channelchek:

College Scholarships for Esports Gamers

How to Invest in Esports

 

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – Namaste Technologies (NXTTF)(N:CA) – Reports Year End 2020 Financial Results


Namaste Technologies Reports Year End 2020 Financial Results

 

TORONTO, March 30, 2021 (GLOBE NEWSWIRE) — Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) a marketplace platform for cannabis and wellness products, today reported its financial results for the year ended November 30, 2020. All financial figures are in Canadian dollars unless otherwise indicated.

Highlights of Consolidated Financial Results:

  • Gross revenue for the fourth quarter ended November 30, 2020 was $8.0 million (compared to $4.0 million in the same period last year), and for the fiscal year ended November 30, 2020 was $27.1 million (compared to $16.4 million in the fiscal year ended November 30, 2019), representing an increase of 100% from the same quarter last year and an increase of 65% from the prior year, respectively.
  • Net revenue for the quarter ended November 30, 2020 was $7.2 million (compared to $3.9 million in the same period last year), and for the fiscal year ended November 30, 2020 was $25.1 million (compared to $16.3 million in the fiscal year ended November 30, 2019), representing an increase of 85% from the same quarter last year, and an increase of 54% from the prior year, respectively.
  • The $3.3 million improvement in net revenue for the fourth quarter ended November 30, 2020 over the same quarter in the prior year ($8.8 million YTD) was primarily attributable to the increased revenues from the sale of cannabis products.
  • The Company’s net loss has shown substantial improvement as compared to 2019. Net loss for the fourth quarter ended November 30, 2020 was ($6.4 million) compared to a net loss of ($29.7 million) for the fourth quarter ended November 30, 2019. Net loss for the fiscal year ended November 30, 2020 was ($26.4 million) compared to a net loss of ($63.2 million) in the fiscal year ended November 30, 2019. The Company is committed to maintaining these positive trends.
  • The Company’s working capital position remains strong at $16.5 million as at November 30, 2020.
  • Subsequent to year-end, the Company successfully closed a $23 million bought deal offering.

Recent Corporate Highlights:

  • Launched CannMart.com into the USA offering Americans hemp derived CBD and smoking accessories.
  • Announced the addition of leading licensed producers to the CannMart.com platform: Auxly Cannabis Group, Hexo Corp and The Green Organic Dutchman Holdings (TGOD).
  • Received a standard processing licence from Health Canada for CannMart Labs Inc., our state-of-the-art BHO extraction facility.
  • Announced expansion to broaden our total addressable market and to evolve into a pre-eminent wellness company, connecting consumers to their wellness needs of tomorrow.

“We are pleased with the progress made by the team to achieve the highest recorded quarterly revenue for the company to date,” said Meni Morim, CEO of Namaste. “We achieved significant year-over-year growth of revenue as cannabis sales through CannMart’s distribution channels made an important contribution to the revenue stream. The Company is in a strong financial position today made possible from the considerable work undertaken in 2020 to lay the foundation for long term growth as Namaste continues its evolution to be the world’s foremost personalized wellness marketplace.”

For further details, the complete Financial Statements for the year-ended ended November 30, 2020 and the related Management’s Discussion & Analysis can be accessed on the Company’s SEDAR profile at www.sedar.com.

NON IFRS FINANCIAL MEASURES

Management evaluates the Company’s performance using a variety of measures, including “Net loss before income tax, depreciation and amortization” and “Adjusted EBITDA”. The non-IFRS measures discussed below should not be considered as an alternative to or to be more meaningful than revenue or net loss. These measures do not have a standardized meaning prescribed by IFRS and therefore they may not be comparable to similarly titled measures presented by other publicly traded companies and should not be construed as an alternative to other financial measures determined in accordance with IFRS.

The Company believes these non-IFRS financial measures provide useful information to both management and investors in measuring the financial performance and financial condition of the Company.

Management uses these and other non-IFRS financial measures to exclude the impact of certain expenses and income that must be recognized under IFRS when analyzing consolidated underlying operating performance, as the excluded items are not necessarily reflective of the Company’s underlying operating performance and make comparisons of underlying financial performance between periods difficult. From time to time, the Company may exclude additional items if it believes doing so would result in a more effective analysis of underlying operating performance. The exclusion of certain items does not imply that they are non-recurring.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ada3b7a0-52a6-4007-917b-f0c10e3ed668

(i) Current and deferred income taxes, depreciation and amortization, and share-based compensation were excluded from the Adjusted EBITDA calculation as they do not represent cash expenditures.

(ii) Other income consisting of gain on disposal of subsidiary, interest income, realized gain on disposition of AFS investments, unrealized gain on derivatives and other miscellaneous non-recurring income were excluded from Adjusted EBITDA calculation.

(iii) Non-recurring costs related to restructuring and legacy issues were excluded from Adjusted EBITDA calculation.

(iv) Impairment loss relating to goodwill, customer list, domains and brand names were excluded from Adjusted EBITDA calculation.

(v) Impairment loss relating to receivable is a provision for expected credit loss to an associate and was excluded from Adjusted EBITDA calculation.

(vi) Share of associates loss, net of tax, is excluded due to lack of control.

About Namaste Technologies Inc.

Headquartered in Toronto, Canada, Namaste Technologies is a marketplace platform for cannabis and wellness products. At CannMart.com, the Company provides Canadian medical customers with a diverse selection of hand-picked products from a multitude of federally licensed cultivators and US customers with access to hemp-derived CBD and smoking accessories. The Company also distributes licensed and in-house branded cannabis and cannabis derived products in Canada through a number of provincial government control boards and retailing bodies and facilitates licensed cannabis retailer sales online in Saskatchewan. Namaste’s global technology and continuous innovation address local needs in a burgeoning cannabis industry requiring smart solutions.

Information on the Company and its many products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

Cannmart.com

For more information please contact:
Namaste Technologies Inc.
Meni Morim, CEO
Edward Miller, VP Investor Relations
Ph: 647-362-0390
Email: ir@namastetechnologies.com

Source: Namaste Technologies Inc

FORWARD-LOOKING INFORMATION – This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen.

The forward-looking information contained herein, including, without limitation, statements related to the Company building the world’s first personalized wellness marketplace and its commitment to continue to reduce its net losses are made as of the date of this press release and is based on assumptions management believed to be reasonable at the time such statements were made, including, without limitation, Namaste’s ability to maintain momentum of expanding its business, its ability to broaden its total addressable market and to evolve into a recognized wellness company, the Company’s expectation that the nutraceutical and wellness market and potentially the market for psychedelics will develop as currently anticipated, the nutraceutical market will continue to be a multi-billion dollar high-margin market, the introduction of new products and brands will generate additional revenue, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: the inability of the Company to develop its business as anticipated and to increase revenues and/or its profitable margin on such revenues, unanticipated changes to current regulations that would adversely impact the Company’s business and proposed business and other regulatory risks, risks relating to the Company’s ability to execute its business strategy and the benefits realizable therefrom and risks specifically related to the Company’s operations. Additional risk factors can also be found in the Company’s current MD&A and annual information form, both of which have been filed under the Company’s SEDAR profile at www.sedar.com. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Source: Namaste Technologies Inc.

Release – Endeavor Silver (EXK) – Announces Board and Management Succession Plans

 


Endeavour Silver Announces Board and Management Succession Plans

 

VANCOUVER, British Columbia, March 30, 2021 (GLOBE NEWSWIRE) — Endeavour
Silver Corp. (TSX: EDR, NYSE: EXK)
(“Endeavour”) announces its forthcoming board and management succession plans.

In anticipation of the re-election of the current directors as proposed in the Management Information Circular for the Annual General Meeting (“AGM”) of Shareholders to be held on May 12, 2021, Geoff Handley, Chair of Endeavour, plans to step down as the Chair of the Board of Directors but will remain active as a Director. Rex McLennan will become the Lead Independent Director at that time.

Bradford Cooke, Chief Executive Officer and Director, has been invited by the Board to assume the role of Executive Chair of Endeavour, and plans to step down as the CEO immediately following the AGM. Dan Dickson, Chief Financial Officer, has been nominated to assume the role of CEO of Endeavour, and Christine West, Vice President Controller, has been nominated to assume the role of CFO of Endeavour.

Bradford Cooke commented, “I am pleased to announce this seamless board and management transition without having to reach outside of the organization. It speaks to the depth of our management team, and the skills and dedication they bring to the Company. I look forward to supporting Dan and Christine in their new roles, and we appreciate the vote of confidence of our Board of Directors.”

“I plan to stay active with Endeavour, utilizing my knowledge of and contacts in the mining industry to continue building a bigger and better Company. However, given that Endeavour is now preparing for its next phase of growth, starting with the construction of the Terronera project this year, now is an appropriate time to pass the baton to our rising stars in management.”

About Endeavour Silver – Endeavour Silver Corp. is a mid-tier precious metals mining company that owns and operates three high-grade, underground, silver-gold mines in Mexico. Endeavour is currently advancing the Terronera mine project towards a development decision and exploring its portfolio of exploration and development projects in Mexico and Chile to facilitate its goal to become a premier senior silver producer. Our philosophy of corporate social integrity creates value for all stakeholders.

SOURCE Endeavour Silver Corp.

Contact Information
Galina Meleger, Director Investor Relations
Toll free: (877) 685-9775
Tel: (604) 640-4804
Email: gmeleger@edrsilver.com
Website: www.edrsilver.com

Follow Endeavour Silver on Facebook, Twitter, Instagram and LinkedIn

Cautionary Note Regarding Forward-Looking Statements

This
news release contains “forward-looking statements” within the meaning of the
United States private securities litigation reform act of 1995 and
“forward-looking information” within the meaning of applicable Canadian
securities legislation. Such forward-looking statements and information herein
include but are not limited to statements regarding Endeavour’s anticipated
performance in 2021 including changes in mining operations and production
levels, the timing and results of various activities and the impact of the
COVID 19 pandemic on operations. The Company does not intend to and does not
assume any obligation to update such forward-looking statements or information,
other than as required by applicable law. 

Forward-looking
statements or information involve known and unknown risks, uncertainties and
other factors that may cause the actual results, level of activity, production
levels, performance or achievements of Endeavour and its operations to be
materially different from those expressed or implied by such statements. Such
factors include but are not limited to the ultimate impact of the COVID 19
pandemic on operations and results, changes in production and costs guidance,
national and local governments, legislation, taxation, controls, regulations
and political or economic developments in Canada and Mexico; financial risks
due to precious metals prices, operating or technical difficulties in mineral
exploration, development and mining activities; risks and hazards of mineral
exploration, development and mining; the speculative nature of mineral
exploration and development, risks in obtaining necessary licenses and permits,
and challenges to the Company’s title to properties; as well as those factors
described in the section “risk factors” contained in the Company’s most recent
form 40F/Annual Information Form filed with the S.E.C. and Canadian securities
regulatory authorities.

Forward-looking statements
are based on assumptions management believes to be reasonable, including but
not limited to: the continued operation of the Company’s mining operations, no
material adverse change in the market price of commodities, mining operations
will operate and the mining products will be completed in accordance with
management’s expectations and achieve their stated production outcomes, and
such other assumptions and factors as set out herein. Although the Company has
attempted to identify important factors that could cause actual results to
differ materially from those contained in forward-looking statements or
information, there may be other factors that cause results to be materially
different from those anticipated, described, estimated, assessed or intended.
There can be no assurance that any forward-looking statements or information
will prove to be accurate as actual results and future events could differ
materially from those anticipated in such statements or information.
Accordingly, readers should not place undue reliance on forward-looking
statements or information.

Release – Genprex (GNPX) – Preclinical Data for TUSC2 Immunogene Therapy in NSCLC to Be Featured


Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 AACR Annual Meeting

 

Two Featured Presentations will Highlight Potential of TUSC2 Immunogene Therapy to Enhance Chemo-Immune Combination Treatments and Overcome Resistance to Osimertinib 

AUSTIN, Texas — (March 30, 2021) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that preclinical data of its TUSC2 immunogene therapy (REQORSA™) in combination with chemotherapy and immunotherapies, as well as in combination with targeted therapies to overcome resistance to osimertinib, for the treatment of non-small cell lung cancer (NSCLC), will be featured in two presentations at the upcoming annual meeting of the American Association for Cancer Research (AACR 21) taking place virtually from April 9-14, 2021.  

“We look forward to the presentation of these data that highlight the potential of TUSC2 immunogene therapy to enhance chemo-immune combination treatments and overcome resistance to osimertinib in lung cancer, to an audience of the world’s leading cancer researchers,” said Rodney Varner, President and Chief Executive Officer of Genprex. “As lung cancer is the leading cause of cancer deaths worldwide, we remain keenly focused on initiating our Acclaim-1 and Acclaim-2 clinical trials to evaluate REQORSA, our proprietary TUSC2 immunogene therapy, in non-small cell lung cancer.”  

Acclaim-1 is a Phase 1/2 combination clinical trial using REQORSA combined with AstraZeneca’s Tagrisso® (osimertinib) in patients with late-stage NSCLC whose disease progressed after treatment with Tagrisso. Acclaim-2 is a Phase 1/2 combination clinical trial using REQORSA combined with Merck & Co’s Keytruda® (pembrolizumab) in NSCLC patients who are low expressors of PD-L1.    

Featured Genprex-supported abstracts to be presented at AACR 21 include: 

Oral Presentation

Session: MS.IM02.02 – Overcoming Resistance in the Tumor Microenvironment: Novel Immunomodulatory Agents

Title: “TUSC2 immunogene therapy enhances efficacy of chemo-immune combination therapy and induces robus antitumor immunity in KRAS-LKB1 mutant NSCLC in humanized mice”

Poster Number/Channel: #76/Channel 03

Presentation Date/Time: April 10, 2021 from 2:50-3:00 p.m. ET

Presenters: Ismail M. Meraz, Mourad Majidi, RuPing Shao, Feng Meng, Min Jin Ha, Elizabeth Shpall, Jack A. Roth. University of Texas MD Anderson Cancer Center, Houston, TX

Poster Presentation

Session: PO.ET03.01 – Drug Resistance in Molecular Targeted Therapies

Title: “Overcoming resistance to osimertinib by TUSC2 gene therapy in EGFR mutant NSCLC”

Poster Number: #1105

Presentation Date/Time: April 10, 2021 from 8:30 a.m. – 11:59 p.m. ET

Presenters: Ismail M. Meraz, Mourad Majidi, RuPing Shao, Lihui Gao, Meng Feng, Huiqin Chen, Min Jin Ha, Jack A. Roth. University of Texas MD Anderson Cancer Center, Houston, TX

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on TwitterFacebook and LinkedIn.

Forward-Looking Statements 

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Company’s future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of REQORSA™ immunogene therapy drug, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining FDA approval of REQORSA and our other potential product candidates including whether we receive or benefit from fast track or similar regulatory designations; costs associated with developing our product candidates, whether we identify and succeed in acquiring other technologies and whether patents will ever be issued under patent applications that are the subject of our license agreements or otherwise. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Genprex, Inc.
(877) 774-GNPX (4679)

Investor Relations
GNPX Investor Relations
(877) 774-GNPX (4679) ext. #2
investors@genprex.com

Media Contact
Genprex Media Relations
(877) 774-GNPX (4679) ext. #3
media@genprex.com

Release – Seanergy Maritime (SHIP) – Acquires its 15th Capesize Vessel and Receives Bank Commitment Letter


Seanergy Maritime Acquires its 15th Capesize Vessel and Receives Bank Commitment Letter

 

GLYFADA, Greece, March 30, 2021 (GLOBE NEWSWIRE) — Seanergy Maritime Holdings Corp. (the “Company”) (NASDAQ: SHIP) announced today that it has entered into a definitive agreement with an unaffiliated third party to purchase a modern Capesize vessel (the “Vessel”). Upon delivery of this acquisition, as well as the previously announced vessel purchases, the size of the Company’s fleet will increase to 15 Capesize vessels with an aggregate cargo capacity of approximately 2.65 million dwt.

The Vessel was built in 2012 at a reputable shipyard in Japan, has a cargo-carrying capacity of approximately 181,300 deadweight tons (“dwt”) and shall be renamed M/V Hellasship. The Vessel is expected to be delivered towards the end of April 2021, subject to the satisfaction of certain customary closing conditions. The ballast water system installation of the Vessel was completed by the current owner and, therefore, no additional costs are envisaged for the Vessel to comply with the relevant regulations. The gross purchase price of $28.6 million is expected to be funded with cash at hand or by a combination of cash at hand and proceeds from new loan facilities.

In addition, the Company received a commitment letter from a European Bank for a $15.5 million loan facility secured by two of its Capesize vessels, the M/V Goodship and the M/V Tradership. The loan will have a tenor of four years from the drawdown date and will bear interest at 4.0% plus LIBOR per annum. The loan remains subject to customary conditions precedent and execution of definitive documentation. Seanergy is also in advanced discussions with leading financial institutions for further financing transactions at competitive terms.

 

Stamatis Tsantanis, the Company’s Chairman & Chief Executive Officer, stated:

“We are pleased to announce the agreement to acquire our 15th Capesize vessel, which will grow our fleet by 50% within the last 9 months. The planning of all our recent acquisitions has been well-timed in light of significantly improved market conditions, which attests to our position as a leading pure-play Capesize company.

Given the prompt delivery prospects, the Company is expected to benefit from the rapidly increasing freight rates. The average of the Baltic Capesize Index currently stands at about $19,000 per day, while the Capesize forward freight contracts (“FFA”) for the second quarter and second half of 2021 are trading at above $22,000 per day on average. Based on these FFA rates, the incremental net revenue from the four recently announced acquisitions may exceed $21 million for the remainder of the year, based on their planned delivery schedule.

Moreover, the new debt financing with the competitive underlying cost, will provide additional liquidity supporting our efforts to successfully execute on our strategic goal of sustainable growth and improved shareholder returns.

The improved prospects of the Capesize market are expected to continue for the coming years and based on our expanded fleet and advantageous employment arrangements, we strongly believe that Seanergy is very well-positioned to benefit from this trend.”

 

Company Fleet upon Vessels’ delivery:

Vessel Name

Vessel Class

Capacity (DWT)

Year Built

Yard

Employment

Partnership

Capesize

179,213

2012

Hyundai

T/C Index Linked

Championship

Capesize

179,238

2011

Sungdong

T/C Index Linked

Lordship

Capesize

178,838

2010

Hyundai

T/C Index Linked

Premiership

Capesize

170,024

2010

Sungdong

T/C Index Linked

Squireship

Capesize

170,018

2010

Sungdong

T/C Index Linked

Knightship

Capesize

178,978

2010

Hyundai

T/C Index Linked

Gloriuship

Capesize

171,314

2004

Hyundai

T/C Index Linked

Fellowship

Capesize

179,701

2010

Daewoo

T/C Index Linked

Geniuship

Capesize

170,058

2010

Sungdong

T/C Index Linked

Goodship

Capesize

177,536

2005

Mitsui Engineering

Voyage/Spot

Leadership

Capesize

171,199

2001

Koyo – Imabari

Voyage/Spot

Tradership

Capesize

176,925

2006

Japanese Shipyard

N/A

Flagship

Capesize

176,387

2013

Japanese Shipyard

N/A

Patriotship

Capesize

181,709

2010

Japanese Shipyard

N/A

Hellasship

Capesize

181,325

2012

Japanese Shipyard

N/A

Total / Average age

2,642,463

11.9

 

About Seanergy Maritime Holdings Corp.

Seanergy Maritime Holdings Corp. is the only pure-play Capesize ship-owner publicly listed in the US. Seanergy provides marine dry bulk transportation services through a modern fleet of Capesize vessels. Upon delivery of the new vessels, the Company’s operating fleet will consist of 15 Capesize vessels with an average age of 11.9 years and aggregate cargo carrying capacity of approximately 2,642,463 dwt.

The Company is incorporated in the Marshall Islands and has executive offices in Glyfada, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP”, its Class A warrants under “SHIPW” and its Class B warrants under “SHIPZ”.

Please visit our company website at: www.seanergymaritime.com

Forward-Looking Statements

This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “should”, “expects”, “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company’s operating or financial results; the Company’s ability to continue as a going concern; the Company’s liquidity, including its ability to service its indebtedness; competitive factors in the market in which the Company operates; shipping industry trends, including charter rates, vessel values and factors affecting vessel supply and demand; future, pending or recent acquisitions and dispositions, business strategy, areas of possible expansion or contraction, and expected capital spending or operating expenses; risks associated with operations outside the United States; risks associated with the length and severity of the ongoing novel coronavirus (COVID-19) outbreak, including its effects on demand for dry bulk products and the transportation thereof; and other factors listed from time to time in the Company’s filings with the SEC, its most recent annual report on Form 20-F. The Company’s filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, the Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information please contact:

Seanergy Investor Relations
Tel: +30 213 0181 522
E-mail: ir@seanergy.gr

Capital Link, Inc.
Daniela Guerrero
230 Park Avenue Suite 1536
New York, NY 10169
Tel: (212) 661-7566
E-mail: seanergy@capitallink.com

Endeavor Silver (EXK) – Announces Board and Management Succession Plans

 


Endeavour Silver Announces Board and Management Succession Plans

 

VANCOUVER, British Columbia, March 30, 2021 (GLOBE NEWSWIRE) — Endeavour
Silver Corp. (TSX: EDR, NYSE: EXK)
(“Endeavour”) announces its forthcoming board and management succession plans.

In anticipation of the re-election of the current directors as proposed in the Management Information Circular for the Annual General Meeting (“AGM”) of Shareholders to be held on May 12, 2021, Geoff Handley, Chair of Endeavour, plans to step down as the Chair of the Board of Directors but will remain active as a Director. Rex McLennan will become the Lead Independent Director at that time.

Bradford Cooke, Chief Executive Officer and Director, has been invited by the Board to assume the role of Executive Chair of Endeavour, and plans to step down as the CEO immediately following the AGM. Dan Dickson, Chief Financial Officer, has been nominated to assume the role of CEO of Endeavour, and Christine West, Vice President Controller, has been nominated to assume the role of CFO of Endeavour.

Bradford Cooke commented, “I am pleased to announce this seamless board and management transition without having to reach outside of the organization. It speaks to the depth of our management team, and the skills and dedication they bring to the Company. I look forward to supporting Dan and Christine in their new roles, and we appreciate the vote of confidence of our Board of Directors.”

“I plan to stay active with Endeavour, utilizing my knowledge of and contacts in the mining industry to continue building a bigger and better Company. However, given that Endeavour is now preparing for its next phase of growth, starting with the construction of the Terronera project this year, now is an appropriate time to pass the baton to our rising stars in management.”

About Endeavour Silver – Endeavour Silver Corp. is a mid-tier precious metals mining company that owns and operates three high-grade, underground, silver-gold mines in Mexico. Endeavour is currently advancing the Terronera mine project towards a development decision and exploring its portfolio of exploration and development projects in Mexico and Chile to facilitate its goal to become a premier senior silver producer. Our philosophy of corporate social integrity creates value for all stakeholders.

SOURCE Endeavour Silver Corp.

Contact Information
Galina Meleger, Director Investor Relations
Toll free: (877) 685-9775
Tel: (604) 640-4804
Email: gmeleger@edrsilver.com
Website: www.edrsilver.com

Follow Endeavour Silver on Facebook, Twitter, Instagram and LinkedIn

Cautionary Note Regarding Forward-Looking Statements

This
news release contains “forward-looking statements” within the meaning of the
United States private securities litigation reform act of 1995 and
“forward-looking information” within the meaning of applicable Canadian
securities legislation. Such forward-looking statements and information herein
include but are not limited to statements regarding Endeavour’s anticipated
performance in 2021 including changes in mining operations and production
levels, the timing and results of various activities and the impact of the
COVID 19 pandemic on operations. The Company does not intend to and does not
assume any obligation to update such forward-looking statements or information,
other than as required by applicable law. 

Forward-looking
statements or information involve known and unknown risks, uncertainties and
other factors that may cause the actual results, level of activity, production
levels, performance or achievements of Endeavour and its operations to be
materially different from those expressed or implied by such statements. Such
factors include but are not limited to the ultimate impact of the COVID 19
pandemic on operations and results, changes in production and costs guidance,
national and local governments, legislation, taxation, controls, regulations
and political or economic developments in Canada and Mexico; financial risks
due to precious metals prices, operating or technical difficulties in mineral
exploration, development and mining activities; risks and hazards of mineral
exploration, development and mining; the speculative nature of mineral
exploration and development, risks in obtaining necessary licenses and permits,
and challenges to the Company’s title to properties; as well as those factors
described in the section “risk factors” contained in the Company’s most recent
form 40F/Annual Information Form filed with the S.E.C. and Canadian securities
regulatory authorities.

Forward-looking statements
are based on assumptions management believes to be reasonable, including but
not limited to: the continued operation of the Company’s mining operations, no
material adverse change in the market price of commodities, mining operations
will operate and the mining products will be completed in accordance with
management’s expectations and achieve their stated production outcomes, and
such other assumptions and factors as set out herein. Although the Company has
attempted to identify important factors that could cause actual results to
differ materially from those contained in forward-looking statements or
information, there may be other factors that cause results to be materially
different from those anticipated, described, estimated, assessed or intended.
There can be no assurance that any forward-looking statements or information
will prove to be accurate as actual results and future events could differ
materially from those anticipated in such statements or information.
Accordingly, readers should not place undue reliance on forward-looking
statements or information.

CanAlaska Uranium (CVVUF)(CVV:CA) – Deals Manibridge Nickel Project in Thompson Nickel Belt Manitoba


CanAlaska Deals Manibridge Nickel Project in Thompson Nickel Belt Manitoba

D Block Discoveries has Staged Option to Earn up to 100% Interest; CanAlaska to be Initial Project Operator

Focus on Advancing High-Grade Sulphide Nickel Discovery

Vancouver, Canada, March 30, 2021 – CanAlaska Uranium Ltd. (TSX-V: CVV; OTCQB: CVVUF; Frankfurt: DH7N) (“CanAlaska” or the “Company”) is pleased to announce that it has entered into a Letter of Intent (“LOI”) with D Block Discoveries Inc. (“DBD”), a private company wholly owned by Ore Group Inc., to allow DBD to earn up to 100% interest in CanAlaska’s 100%-owned 4,368 hectare Manibridge Nickel Project in Manitoba, Canada (the “Project”) (Figure 1).

DBD may earn up to a 100% interest in the Project by undertaking work and payments in three defined earn-in stages. DBD may earn an initial 49% interest (“Stage 1”) in the Project by paying the Company $30,000 cash, issue $275,000 worth of common shares and incur $500,000 in exploration expenditures on the Project within 12 months of TSX Venture Exchange approval date. DBD may earn an additional 21% interest (“Stage 2”) in the Project by paying to the Company a further $50,000 cash, issue a further 1,500,000 common shares in DBD, and incur an additional $1,500,000 in exploration expenditures on the Project within 12 months of entering the Stage 2 option. DBD may earn an additional 30% interest (“Stage 3”) in the Project by paying to the Company a further $100,000 cash, issue a further 5,000,000 common shares in DBD, and incur an additional $2,000,000 in exploration expenditures on the Project within 24 months of entering the Stage 3 option.

After successful completion of either of Stage 1 or Stage 2 of the option agreement, and if DBD elects to not enter the final stage, a joint venture will be formed and the parties will either co-contribute on a simple pro-rata basis or dilute on a pre-defined straight-line dilution formula. A summary of the various stages is contained in Table 1.

During Stage 1 and Stage 2 of the option agreement, CanAlaska will be operator of the Project. DBD will have sole voting rights on exploration programs while sole funding at the various option stages and will have the right to assume operatorship after successfully earning 70% interest in the Project (Stage 2).

As part of completing the Stage 1 option, DBD will grant to CVV a 1% Net Smelter Return (NSR) royalty on claims P1271F and P1272F, and a 2% NSR royalty on all other claims.

Table 1: Summary of Option Stages

Option Stage DBD
Interest
Earned
(%)
Cash
Payment
($)
DBD Shares
Issued
Exploration
Expenditure
($)
Timeline
(months)
On signing 15,000
On CPC merger 15,000 $100,000 eq. On TSX Approval
Stage 1 49 $175,000 eq. 500,000 12
Stage 2 21 50,000 1,500,000 1,500,000 12
Stage 3 30 100,000 5,000,000 2,000,000 24
Totals 100 180,000 6,500,000* 4,000,000 36


*Does not include the $275,000 worth of share issuance

Manibridge Nickel Project

The Manibridge nickel deposit was discovered in 1963 by Falconbridge (as Glencore was then named) following up on coincident magnetic and electromagnetic anomalies that were thought to be caused by an ultramafic body. The second hole of the program intersected the fringes of what would become the Manibridge Mine. Sulphide nickel mineralization is hosted within an elongate, folded ultramafic body that extends for at least 3.2 kilometres with nickel-bearing sulphide mineralization throughout (Figure 1). The Manibridge nickel deposit is located within the core of a major fold axis with up to ten sulphide lenses that conform to the fold pattern and plunge to depths in excess of 380 metres.

A production decision was made in 1969 on an initial mineral inventory of 1,409,000 tons (including 15% dilution) at an average grade of 2.25% nickel and 0.27% copper to a depth of 380 metres. The mine was operational from 1971 to 1977 with concentrate shipped to both Sudbury, Ontario and Thompson, Manitoba. Mining occurred to a depth of 300 metres and the mine infrastructure has since been reclaimed.


Manibridge Project – Location and Geology Map

In 2007, Crowflight Minerals Inc. and Pure Nickel formed a 50-50% joint venture to explore the Manibridge claims. The 2008 exploration program intersected two new zones of nickel mineralization within 400 metres of the Manibridge deposit. Further drilling confirmed the extension of the mineralization below the mine workings. The most significant results from drill holes MN08-01, MN08-02 and MN08-04 respectively include: 16.75 metres (55 feet) @ 1.38% Ni; 5.45 metres (17.9 feet) @ 1.18% Ni; and 6.3 metres (20.7 feet) @ 1.37% Ni.

In 2019 a 800 metre drill program completed by CanAlaska 2.5 kilometres north along the mine trend intersected a broad fold structure that included multiple high-grade nickel assays up to 12.06% nickel,

CanAlaska President, Peter Dasler, comments, “CanAlaska is pleased to be able to work with D-Block’s entrepreneurial group, and management is looking forward to operating the next exploration programs and new discoveries at Manibridge, as well as being exposed to the new company’s other exploration interests.”

About D Block Discoveries

D Block Discoveries Inc. is privately held wholly owned private company controlled by Ore Group Inc. DBD controls the Strange Nickel Project, an 11,000-hectare, drill permitted nickel, copper, PGE exploration property west of Thunder Bay, Ontario. DBD is planning its going public process for listing on the TSX Venture Exchange in the near term. Further information can be found at DBD’s website.

Other News

CanAlaska is currently conducting drilling at its 100% owned Waterbury Uranium project in the Athabasca Basin near the Cigar Lake uranium mine. The Company is also awaiting drill results from its Mouse Mountain copper property in British Columbia, and drilling permits for the Strong nickel project in Manitoba.

About CanAlaska Uranium

CanAlaska Uranium Ltd. (TSX-V: CVV; OTCQB: CVVUF; Frankfurt: DH7N) holds interests in approximately 214,000 hectares (530,000 acres), in Canada’s Athabasca Basin – the “Saudi Arabia of Uranium.” CanAlaska’s strategic holdings have attracted major international mining companies. CanAlaska is currently working with Cameco and Denison at two of the Company’s properties in the Eastern Athabasca Basin. CanAlaska is a project generator positioned for discovery success in the world’s richest uranium district. The Company also holds properties prospective for nickel, copper, gold and diamonds. For further information visit www.canalaska.com.

The qualified technical person for this news release is Dr Karl Schimann, P. Geo, CanAlaska director and VP Exploration.

On behalf of the Board of Directors

“Peter Dasler”
Peter Dasler, M.Sc., P.Geo.
President & CEO
CanAlaska Uranium Ltd.

Contacts:

Peter Dasler, President
Tel: +1.604.688.3211 x 138
Email: info@canalaska.com

Cory Belyk, COO
Tel: +1.604.688.3211 x 138
Email: cbelyk@canalaska.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information

All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.

Release – CanAlaska Uranium (CVVUF)(CVV:CA) – Deals Manibridge Nickel Project in Thompson Nickel Belt Manitoba


CanAlaska Deals Manibridge Nickel Project in Thompson Nickel Belt Manitoba

D Block Discoveries has Staged Option to Earn up to 100% Interest; CanAlaska to be Initial Project Operator

Focus on Advancing High-Grade Sulphide Nickel Discovery

Vancouver, Canada, March 30, 2021 – CanAlaska Uranium Ltd. (TSX-V: CVV; OTCQB: CVVUF; Frankfurt: DH7N) (“CanAlaska” or the “Company”) is pleased to announce that it has entered into a Letter of Intent (“LOI”) with D Block Discoveries Inc. (“DBD”), a private company wholly owned by Ore Group Inc., to allow DBD to earn up to 100% interest in CanAlaska’s 100%-owned 4,368 hectare Manibridge Nickel Project in Manitoba, Canada (the “Project”) (Figure 1).

DBD may earn up to a 100% interest in the Project by undertaking work and payments in three defined earn-in stages. DBD may earn an initial 49% interest (“Stage 1”) in the Project by paying the Company $30,000 cash, issue $275,000 worth of common shares and incur $500,000 in exploration expenditures on the Project within 12 months of TSX Venture Exchange approval date. DBD may earn an additional 21% interest (“Stage 2”) in the Project by paying to the Company a further $50,000 cash, issue a further 1,500,000 common shares in DBD, and incur an additional $1,500,000 in exploration expenditures on the Project within 12 months of entering the Stage 2 option. DBD may earn an additional 30% interest (“Stage 3”) in the Project by paying to the Company a further $100,000 cash, issue a further 5,000,000 common shares in DBD, and incur an additional $2,000,000 in exploration expenditures on the Project within 24 months of entering the Stage 3 option.

After successful completion of either of Stage 1 or Stage 2 of the option agreement, and if DBD elects to not enter the final stage, a joint venture will be formed and the parties will either co-contribute on a simple pro-rata basis or dilute on a pre-defined straight-line dilution formula. A summary of the various stages is contained in Table 1.

During Stage 1 and Stage 2 of the option agreement, CanAlaska will be operator of the Project. DBD will have sole voting rights on exploration programs while sole funding at the various option stages and will have the right to assume operatorship after successfully earning 70% interest in the Project (Stage 2).

As part of completing the Stage 1 option, DBD will grant to CVV a 1% Net Smelter Return (NSR) royalty on claims P1271F and P1272F, and a 2% NSR royalty on all other claims.

Table 1: Summary of Option Stages

Option Stage DBD
Interest
Earned
(%)
Cash
Payment
($)
DBD Shares
Issued
Exploration
Expenditure
($)
Timeline
(months)
On signing 15,000
On CPC merger 15,000 $100,000 eq. On TSX Approval
Stage 1 49 $175,000 eq. 500,000 12
Stage 2 21 50,000 1,500,000 1,500,000 12
Stage 3 30 100,000 5,000,000 2,000,000 24
Totals 100 180,000 6,500,000* 4,000,000 36


*Does not include the $275,000 worth of share issuance

Manibridge Nickel Project

The Manibridge nickel deposit was discovered in 1963 by Falconbridge (as Glencore was then named) following up on coincident magnetic and electromagnetic anomalies that were thought to be caused by an ultramafic body. The second hole of the program intersected the fringes of what would become the Manibridge Mine. Sulphide nickel mineralization is hosted within an elongate, folded ultramafic body that extends for at least 3.2 kilometres with nickel-bearing sulphide mineralization throughout (Figure 1). The Manibridge nickel deposit is located within the core of a major fold axis with up to ten sulphide lenses that conform to the fold pattern and plunge to depths in excess of 380 metres.

A production decision was made in 1969 on an initial mineral inventory of 1,409,000 tons (including 15% dilution) at an average grade of 2.25% nickel and 0.27% copper to a depth of 380 metres. The mine was operational from 1971 to 1977 with concentrate shipped to both Sudbury, Ontario and Thompson, Manitoba. Mining occurred to a depth of 300 metres and the mine infrastructure has since been reclaimed.


Manibridge Project – Location and Geology Map

In 2007, Crowflight Minerals Inc. and Pure Nickel formed a 50-50% joint venture to explore the Manibridge claims. The 2008 exploration program intersected two new zones of nickel mineralization within 400 metres of the Manibridge deposit. Further drilling confirmed the extension of the mineralization below the mine workings. The most significant results from drill holes MN08-01, MN08-02 and MN08-04 respectively include: 16.75 metres (55 feet) @ 1.38% Ni; 5.45 metres (17.9 feet) @ 1.18% Ni; and 6.3 metres (20.7 feet) @ 1.37% Ni.

In 2019 a 800 metre drill program completed by CanAlaska 2.5 kilometres north along the mine trend intersected a broad fold structure that included multiple high-grade nickel assays up to 12.06% nickel,

CanAlaska President, Peter Dasler, comments, “CanAlaska is pleased to be able to work with D-Block’s entrepreneurial group, and management is looking forward to operating the next exploration programs and new discoveries at Manibridge, as well as being exposed to the new company’s other exploration interests.”

About D Block Discoveries

D Block Discoveries Inc. is privately held wholly owned private company controlled by Ore Group Inc. DBD controls the Strange Nickel Project, an 11,000-hectare, drill permitted nickel, copper, PGE exploration property west of Thunder Bay, Ontario. DBD is planning its going public process for listing on the TSX Venture Exchange in the near term. Further information can be found at DBD’s website.

Other News

CanAlaska is currently conducting drilling at its 100% owned Waterbury Uranium project in the Athabasca Basin near the Cigar Lake uranium mine. The Company is also awaiting drill results from its Mouse Mountain copper property in British Columbia, and drilling permits for the Strong nickel project in Manitoba.

About CanAlaska Uranium

CanAlaska Uranium Ltd. (TSX-V: CVV; OTCQB: CVVUF; Frankfurt: DH7N) holds interests in approximately 214,000 hectares (530,000 acres), in Canada’s Athabasca Basin – the “Saudi Arabia of Uranium.” CanAlaska’s strategic holdings have attracted major international mining companies. CanAlaska is currently working with Cameco and Denison at two of the Company’s properties in the Eastern Athabasca Basin. CanAlaska is a project generator positioned for discovery success in the world’s richest uranium district. The Company also holds properties prospective for nickel, copper, gold and diamonds. For further information visit www.canalaska.com.

The qualified technical person for this news release is Dr Karl Schimann, P. Geo, CanAlaska director and VP Exploration.

On behalf of the Board of Directors

“Peter Dasler”
Peter Dasler, M.Sc., P.Geo.
President & CEO
CanAlaska Uranium Ltd.

Contacts:

Peter Dasler, President
Tel: +1.604.688.3211 x 138
Email: info@canalaska.com

Cory Belyk, COO
Tel: +1.604.688.3211 x 138
Email: cbelyk@canalaska.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information

All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.

Is There Opportunity in the Suez Predicament?

 


Is There Opportunity in the Suez Predicament?

 

Just shy of a week after its becoming lodged in the Suez Canal, teams have made some progress on the 1,300-foot ship owned by the Taiwanese company Evergreen Marine Corp. This has brought needed hope that the busy trade route could soon reopen. Clearing the stranded ship would help take its owners out of what has been a harsh global reaction. And it’s no wonder why it has been so pointed; although the shipping industry is expected to recover from the Suez incident, shipping is considered one of the important post-pandemic recovery sectors as global commerce builds to a more normal pace. The industry had a nightmarish 2020, that was coming to an end. In fact, two weeks before the ships grounding on March 23rd, many shipping companies began to rally, outperforming the S&P 500. They have dipped since the mishap. This dip may open an opportunity for investors that missed the initial run. 

Notable companies whose research is available here on Channelchek are Pyxis Tankers (PXS) up 5.56% over the past month. Seanergy (SHIP) is off its highs but still up 7.44%, Genco Shipping (GNK) is up 9.18% after this incident, Grindrod Shipping (GRIN) 10.44%, Euroseas (ESEA) is down from its 2021 peak on March 15th but still up a sizeable 26.69% on the month, and Eurodry’s (EDRY) ascent seems to have slowed with a current gain of 24.83% month over month.

 

 

The below info-graphic provided by Visual
Capitalist
shows the disruption this temporary event has on global shipping as 12% of all physical global trade passes through the Suez Canal.

 

 

Feel free to share this information.

Questions/comments can be directed to the Channelchek Team.

 

Related Investor Information:


NobleCon17 Transportation Panel Video

D


Why Oil Prices Can Continue Going Up


Release – Helius Medical Technologies (HSDT)(HSM:CA) – FDA Authorizes Marketing of Device to Improve Gait in Multiple Sclerosis Patients

 


FDA Authorizes Marketing of Device to Improve Gait in Multiple Sclerosis Patients

 

Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS). The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older. The device, called Portable Neuromodulation Stimulator (PoNS), is a neuromuscular tongue stimulator that consists of a non-implantable apparatus to generate electrical pulses for stimulation of the trigeminal and facial nerves via the tongue to provide treatment of motor deficits.

“MS is one of the most common neurological diseases in young adults. Today’s authorization offers a valuable new aid in physical therapy and increases the value of additional therapies for those who live with MS on a daily basis,” said Christopher M. Loftus, M.D., acting director of the Office of Neurological and Physical Medicine Devices in the FDA’s Center for Devices and Radiological Health.

MS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communications between the brain and other parts of the body. According to the National Institute of Neurological Disorders and Stroke, most people experience their first symptoms of MS between the ages of 20 and 40 and the disease occurs more frequently in women than in men. MS is a disease that affects people differently as it causes a variety of symptoms—such as problems with walking and balance—that can interfere with daily activities but can usually be treated or managed. The most common walking problem is unsteady, uncoordinated movements (known as ataxia) due to damage to the areas of the brain that coordinate muscle balance. People with severe ataxia generally benefit from the use of a cane, walker, or other assistive device. Physical therapy can also reduce walking problems.

The PoNS device is a portable, non-implantable device which delivers mild neuromuscular electrical stimulation to the dorsal surface of the patient’s tongue. It consists of a controller and a mouthpiece that are connected to each other by a cord. The mouthpiece is held lightly in place by the lips and teeth and the control unit is worn around the neck during a patient’s visit with a therapist. The controller sends signals to the mouthpiece placed on the tongue; receptors on the tongue send millions of neural impulses to the brain through natural pathways. Additionally, the therapist can connect the control unit to a computer and view usage data via software developed specifically for the PoNS device. The usage data gives the therapist information on how to improve a patient’s execution of therapy by identifying potential areas of missed or shortened sessions.

The FDA assessed the safety and effectiveness of the PoNS device through two clinical studies and a retrospective analysis of real-world data (RWD). In the first study, 20 patients with gait deficits due to MS participated in a randomized, double blind controlled trial where 10 patients used the PoNS device and the remaining 10 patients used a sham control device that did not deliver stimulation. The primary outcome measure was the Dynamic Gait Index (DGI) where the clinician scored an index of eight gait tasks. The DGI was assessed for a baseline, at two weeks, six weeks, 10 weeks, and 14 weeks. The results showed that the PoNS group on average achieved improvement in their DGI score of 7.95 at the end of the study, which was statistically significant and clinically significant, while the control group did not.

In the second study, the clinicians investigated the effects of the PoNS device with cognitive rehab and physical rehab in 14 patients with MS, who did not know whether they had the PoNS device or the sham control device, in a randomized controlled trial where seven patients used the PoNS device and the other seven used a sham device. Baseline evaluations included sensory organization tasks (SOT) and DGI scores. The PoNS device group showed a statistically significant improvement in SOT scores at 14 weeks compared to the baseline value. Analysis of DGI scores after 14 weeks showed no significant result.

The sponsor also provided a retrospective analysis of RWD collected with the PoNS device in MS patients in clinical rehabilitation settings. Patients who agreed to treatment were given 1-hr consultation, provided consent, and given baseline assessments of gait function using Functional Gait Assessment. No serious safety adverse events were reported in the clinical studies or retrospective analysis of RWD.

The PoNS device should not be used by patients with penetrating brain injuries, neurodegenerative diseases, oral health problems, chronic infectious diseases, unmanaged hypertension or diabetes, pacemakersand/or a history of seizures. Because the PoNS device delivers electrical stimulation directly to the surface of the tongue, precautions for use are similar to those for transcutaneous electrical nerve stimulation. Electrical stimulation should not be used if there is an active or suspected malignant tumor; in areas of recent bleeding or open wounds; or in areas that lack normal sensation. The PoNS device has not been tested on, and thus should not be used by, individuals under the age of 22 or who are pregnant. The PoNS device should not be used if a patient is sensitive to nickel, gold or copper.

Patients should use the PoNS device with caution, and electrical stimulation should only be used after seeking professional medical advice. For a full list of warnings and precautions to consider if using the PoNS device, please consult the device labeling.

The PoNS device was granted Breakthrough Device designation, which is a process designed to expedite the development and review of devices that may provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.

The FDA reviewed the PoNS device through the De Novo premarket review pathway, a regulatory pathway for low-to moderate-risk devices of a new type. Along with this authorization, the FDA is establishing special controls for devices of this type, including requirements related to labeling and performance testing. When met, the special controls, along with general controls, provide reasonable assurance of safety and effectiveness for devices of this type. This action creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through the FDA’s 510(k) premarket process, whereby devices can obtain clearance by demonstrating substantial equivalence to a predicate device.

The FDA granted marketing authorization of the Portable Neuromodulation Stimulator to Helius Medical, Inc.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Source: fda.gov

Helius Medical Technologies (HSDT)(HSM:CA) – FDA Approval of PoNS for MS

Monday, March 29, 2021

Helius Medical Technologies (HSDT)(HSM:CA)
FDA Approval of PoNS for MS

Helius Medical Technologies Inc are a medical technology company. It is focused on the development of products for the treatment of neurological symptoms caused by disease or trauma. The company has developed its first, known as the portable neuromodulation stimulator or PoNS, device, is designed to enhance the brain’s ability to compensate for this damage.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    FDA Approval. On Friday, the U.S. Food and Drug Administration authorized marketing of the PoNS device for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS). The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older. With over one million MS patients in the U.S., this is the largest market for which the PoNS treatment has received approval.

    FDA Comment.  According to Christopher M. Loftus, M.D., acting director of the Office of Neurological and Physical Medicine Devices in the FDA’s Center for Devices and Radiological Health, “MS is one of the most common neurological diseases in young adults. Today’s authorization offers a valuable new aid in physical therapy and increases the value of additional therapies for those who live with MS …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Bunker Hill Mining (BHLL)(BNKR:CA) – Reports Multiple High-Grade Silver Mineralization Results


Bunker Hill Announces 3.8 Meters at 997 Ag Eq g/t Drill Intercept, Ten Channel Samples Above 900 Ag Eq g/t Including 0.6 Meters at 3,003 Ag Eq

 

Bunker Hill Announces 3.8 Meters at 997 Ag Eq g/t Drill Intercept, Ten Channel Samples Above 900 Ag Eq g/t Including 0.6 Meters at 3,003 Ag Eq

Bunker Hill to Host a Webinar on Wednesday, March 31 @ 8:00am PT/11:00am ET

HIGHLIGHTS:

  • Ten
    separate high-grade silver mineralization results greater than 900 g/t
    AgEq 1 , each with minimum 0.6m length, identified through targeted
    chip-channel sampling in newly accessible part of 9-level Deadwood vein
    • Best
      selected chip sample includes 0.6m at 1,100 g/t Ag and 60% Pb,
      representing 3,002.6 g/t AgEq 1
    • Mineralization
      remains open up dip, down dip and along strike from the sampling location
    • Follow-up
      diamond drilling is planned to test the extent of the Deadwood vein and
      nearby Jersey vein
  • High-grade
    silver, lead and zinc mineralization, including 3.8m at 197 g/t Ag, 21.2%
    Pb and 2.7% Zn, representing 996.6 g/t AgEq 1 , intersected at
    down-dip extension of the UTZ zone at the 5-level
  • Executive
    Chairman Richard Williams, CEO Sam Ash, and CFO David Wiens to host live
    interactive 6ix virtual investor event on Wednesday, March 31st at 11:00AM
    ET / 8:00AM PT to discuss these results, ongoing silver exploration and
    other near-term catalysts. Investors are invited to register for this
    event at:
    LINK

TORONTO, March 29, 2021 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (CSE: BNKR) (“Bunker Hill” or the “Company”) is pleased to report multiple high-grade silver mineralization results as part of its ongoing silver-focused drilling program, and through chip-channel sampling of newly accessible areas of the Bunker Hill Mine identified through the Company’s proprietary 3D digitization program.

Sam Ash, CEO of Bunker Hill, stated: “Having completed the drilling campaign designed to support the mine restart plan and associated PEA, we have now shifted our drilling and sampling focus to high-grade silver exploration in order to bring more silver into our upper mine resources and future mine planning.

Today’s results confirm high grade silver mineralization in two distinct areas of the upper mine close to existing infrastructure. Firstly, we have confirmed the silver potential of the Deadwood vein through ten separate high-grade channel samples. Secondly, our systematic targeting methodology allowed us to confirm the presence of high-grade silver mineralization on the 5-level through drilling, within an area where no historical mining was conducted. Both of these areas, along with others, will be followed up and developed over the coming weeks.”

Channel Sampling at the
9-Level Results in Ten Separate High-Grade Silver Mineralization Results

As a result of the digitization of the historic mine data and underground reconnaissance, an area was identified on the 9-level with access to the Deadwood vein: a shallow dipping galena-quartz (“GQ”) silver-lead vein that was mined until mine closure. The vein is exposed in the footwall rib of an historic stope over roughly 35 feet horizontally, with the thickness of mineralized exposure ranging from roughly 1 to 2 meters. Chip samples were collected from 10 vertical channels on the footwall rib designed to approximately crosscut the strike of the vein. See Figure 1 showing the sample distribution and resulting grades.

Digitization and reconnaissance efforts indicate that silver-lead mineralization from the Deadwood vein remains open to testing up-dip, down dip and along strike to the west. Follow up diamond drilling is planned to test the extent of the Deadwood vein and nearby Jersey vein, another historically mined GQ silver-lead vein on the 9 Level of the mine.

______________________________
1 Prices used to calculate Ag Eq are as follows: Zn=$1.16/lb; Pb=$0.92/lb; and Ag=$20/oz.

Figure 1: 090-23-21 Deadwood
Vein Stope – Floor 4 Footwall Rib Channel Samples

https://www.globenewswire.com/NewsRoom/AttachmentNg/6e30b1cd-59c5-4713-95c4-84a9328e8c8a

Channel sample assays results are presented in the Table 1 below.

TABLE 1: CHANNEL SAMPLE ASSAYS

Channel

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

1

0

0.9

0.9

317.5

56.8

8.2

0

0.9

2.1

1.2

135.1

4

4.1

0

Channel

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

2

0

1.2

1.2

1156.7

497

20.9

0

1.2

2.4

1.2

69.4

4.4

2.1

0

Channel

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

3

0

0.6

0.6

1022.2

312

22.5

0

0.6

1.2

0.6

1618.9

940

21.5

0

1.2

1.8

0.6

161.2

21.6

4.4

0

Channel

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

4

0

1.2

1.2

955

336

19.6

0

Channel

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

5

0

1.2

1.2

412.4

96

10

0

1.2

2.1

0.9

1199.6

549

20.6

0

Channel

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

6

0

0.9

0.9

1228.7

581

20.5

0

0.9

1.8

0.9

1054.2

377

21.4

0.1

Channel

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

7

0

1.2

1.2

737

206

16.8

0

1.2

2.1

0.9

901

288

19.4

0

Channel

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

8

0

0.9

0.9

49.2

2.5

1.4

0.1

0.9

1.8

0.9

975.1

343

20

0

Channel

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

9

0

0.6

0.6

85.7

17.3

2.2

0

0.6

1.2

0.6

3002.6

1100

60.3

0

Channel

From

To

M

AgEq g/t

g/t Ag

%Pb

%Zn

10

0

0.6

0.6

21.3

2.6

0.6

0

0.6

1.5

0.9

40.1

20.3

0.6

0

(Reported widths are actual
sampled interval lengths and do not state the true width of the mineralized
structure. Samples were taken in a manner to reflect, as closely as possible,
true structural width. Prices used to calculate AgEq are as follows: Zn=$1.16/lb;
Pb=$0.92/lb; and Ag=$20/oz.)

Drilling at the 5-Level
Results in Nearly 4-Meter Intercept at Approximately 1,000 g/t AgEq

Concurrently, drilling from the 5-level UTZ intersected high-grade silver-lead-zinc mineralization below the UTZ fingers zone, as part of exploring for near-surface silver targets. The Company is excited to report a 3.8m intercept with a grade of 996.6 g/t AgEq, as indicated in Table 2 below. Intercepted mineralization in hole 7069 (see Figure 2 below showing cross-section and Figure 3 below showing drill core) lies near existing rehabilitated infrastructure, providing low-cost access to the zone for mining under Bunker Hill’s Phase 1 program of the Rapid Restart Plan. Follow up drilling will explore the extent of the mineralization and increase the understanding of the geology in the area.

The drill results in the table below represent the most recent assay data available since the Company’s news release dated February 26, 2021; the Company will continue to report mineralized drill intercepts concurrent with its ongoing exploration program that is currently envisaged to comprise 10,000 to 12,000 feet in 2021.

TABLE 2: HIGH-GRADE SILVER
INTERCEPT FROM HOLE 7069

7069

From

To

M

AgEq

g/t Ag

%Pb

%Zn

44.5

48.3

3.8

996.6

197

21.2

2.7

Including

45.7

46.3

0.6

706.5

164

15.3

1.5

46.3

47.2

0.9

1491.7

350

28.6

5.9

47.2

48.3

1.1

1462.0

310

31.8

3.7

 

7069

From

To

M

AgEq

g/t Ag

%Pb

%Zn

52.4

53.3

0.9

755.3

160

15.9

2.3

(Reported widths are
intercepted ore lengths and not true widths, as relationships with intercepted
structures and contacts vary. Prices used to calculate AgEq are as follows:
Zn=$1.16/lb, Pb=$0.92/lb, Ag=$20/oz.)

Figure 2: Cross section of
hole 7069

https://www.globenewswire.com/NewsRoom/AttachmentNg/11b3bb0c-606c-478d-ab42-22e391a9ecb8

Figure 3: Drill Core from
hole 7069

https://www.globenewswire.com/NewsRoom/AttachmentNg/057e8c21-a292-4690-aef4-4209f48e9b08

The preliminary economic assessment (“PEA”), aimed at assessing the mine’s rapid restart potential, remains on track to be published in early Q2 2021.

WEBINAR

Bunker Hill will host a
webinar to discuss the Company’s recent results and future exploration plans.
The webinar will take place on Wednesday, March 31 at 8:00 am PT/11:00am
EST. Management will be available to answer questions following the
presentation.

To join the webinar,
register from this link (also includes dial-in instructions):

Link: UPCOMING EVENTS

Adelaide Capital Idaho Conference
April 8, 2021 @ 12:00pm ET – 4:00pm ET
Join Us:
REGISTER NOW

World Gold Forum
April 13-15, 2021
https://www.worldgoldforum.com/

HC Wainwright Mining Conference

April 19-20, 2021
Join Us: REGISTER NOW

121 Mining Investment Americas
April 27-29, 2021
https://www.weare121.com/121mininginvestment-new-york/

TECHNICAL INFORMATION

Chip-channel samples were collected by hand using hammer and chisel perpendicularly across exposed mineralized structures to best represent the true width and nature of the material present. Sample collar locations were surveyed using modern survey techniques to provide positioning of each sample in three-dimensional space. Bunker Hill followed standard quality assurance/quality control (“QA/QC”) practices to ensure the integrity of samples through collection, preparation and delivery of samples to the lab. All sample locations have been photographed, with channel traces spray painted to indicate the location and orientation of each sample. Standards of certified reference materials, field duplicates and blanks were inserted as samples shipped with the chip samples to the lab.

The diamond drilling program used HQ-size core. Bunker Hill followed standard QA/QC practices to ensure the integrity of the core and sample preparation through delivery of the samples to the assay lab. The drill core was stored in a secure facility, photographed, logged, split into halves and sampled based on lithologic and mineralogical interpretations. Standards of certified reference materials, field duplicates and blanks were inserted as samples shipped with the core samples to the lab.

American Analytical Services (“AAS”) was used to provide analytical services and all results comply with both National Instrument 43-101 – Standards of Disclosure for
Mineral Projects
(“NI 43-101”) and industry standards. AAS holds an industry standard ISO 17025:2005 accreditation, specifying general requirements for laboratory performance. AAS is independent from Bunker Hill.

QUALIFIED PERSON

Mr. Scott E. Wilson, CPG, President of Resource Development Associates Inc. and a consultant to the Company, is an independent qualified person as defined by NI 43-101 and is acting as the qualified person for the Company. He has reviewed and approved the technical information summarized in this news release.

ABOUT BUNKER HILL MINING CORP.

Under new Idaho-based leadership, Bunker Hill Mining Corp. intends to sustainably restart and develop the Bunker Hill Mine as the first step in consolidating a portfolio of North American precious-metal assets with a focus on silver. Information about the Company is available on its website, www.bunkerhillmining.com, or under the Company’s profile on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.

For additional information contact:

Sam Ash, President and Chief Executive Officer
+1 208 786 6999
sa@bunkerhillmining.com

CAUTIONARY STATEMENTS

Certain statements in this news
release are forward-looking and involve a number of risks and uncertainties.
Such forward-looking statements are within the meaning of that term in Section
27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, as well as within the meaning of
the phrase ‘forward-looking information’ in the Canadian Securities
Administrators’ National Instrument 51-102 – Continuous Disclosure Obligations.
Forward-looking statements are not comprised of historical facts.
Forward-looking statements include estimates and statements that describe the
Company’s future plans, objectives or goals, including words to the effect that
the Company or management expects a stated condition or result to occur.
Forward-looking statements may be identified by terminology such as “may”,
“will”, “could”, “should”, “expect”, “plan”, “anticipate”, “believe”, “intend”,
“estimate”, “projects”, “predict”, “potential”, “continue” or other similar
expressions concerning matters that are not historical facts.

Since forward-looking
statements are based on assumptions and address future events and conditions,
by their very nature they involve inherent risks and uncertainties. Although
these statements are based on information currently available to the Company,
the Company provides no assurance that actual results will meet management’s
expectations. Risks, uncertainties and other factors involved with
forward-looking information could cause actual events, results, performance,
prospects and opportunities to differ materially from those expressed or
implied by such forward-looking information. The key risks and uncertainties
include, but are not limited to: local and global political and economic
conditions; governmental and regulatory requirements and actions by
governmental authorities, including changes in government policy, government
ownership requirements, changes in environmental, tax and other laws or
regulations and the interpretation thereof; developments with respect to the
coronavirus disease 2019 (“COVID-19”) pandemic, including the duration,
severity and scope of the pandemic and potential impacts on mining operations;
and other risk factors detailed from time to time in the Company’s reports
filed on SEDAR and EDGAR.

Forward-looking information
and statements in this news release include statements concerning, among other things:
the Company’s intention to conduct follow up drilling to test the extent of the
Deadwood vein and nearby Jersey vein; the Company’s intention to conduct follow
up drilling from the 5-level of the mine to explore the extent of the
mineralization and increase the understanding of the geology in the area; the
timing for publishing the PEA aimed at assessing the mine’s rapid restart
potential; and the Company’s intentions regarding its objectives, goals or
future plans and statements. Factors that could cause actual results to differ
materially from such forward-looking information include, but are not limited
to: the ability to predict and counteract the effects of COVID-19 on the
business of the Company, including but not limited to the effects of COVID-19
on the price of commodities, capital market conditions, restriction on labor
and international travel and supply chains; failure to identify mineral
resources; failure to convert estimated mineral resources to reserves; the
inability to complete a feasibility study which recommends a production
decision; the preliminary nature of metallurgical test results; delays in
obtaining or failures to obtain required governmental, environmental or other
project approvals; political risks; changes in equity markets; uncertainties
relating to the availability and costs of financing needed in the future; the
inability of the Company to budget and manage its liquidity in light of the
failure to obtain additional financing, including the ability of the Company to
complete the payments pursuant to the terms of the agreement to acquire the
Bunker Hill Mine Complex; inflation; changes in exchange rates; fluctuations in
commodity prices; delays in the development of projects; capital, operating and
reclamation costs varying significantly from estimates and the other risks
involved in the mineral exploration and development industry; and those risks
set out in the Company’s public documents filed on SEDAR and EDGAR. Although
the Company believes that the assumptions and factors used in preparing the
forward-looking information in this news release are reasonable, undue reliance
should not be placed on such information, which only applies as of the date of
this news release, and no assurance can be given that such events will occur in
the disclosed time frames or at all. The Company disclaims any intention or
obligation to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise, other than as required
by law. No stock exchange, securities commission or other regulatory authority
has approved or disapproved the information contained herein.


Source: Bunker Hill Mining